The relief trade is back on trial — and the verdict starts today. US and Iranian negotiators convene in Switzerland this morning, with Vice-President JD Vance attending and an emergency session on the Israel–Hezbollah conflict bumped to the top of the agenda. The path there was rocky: a Friday Israel–Hizbollah ceasefire frayed within a day, and Iran declared the Strait of Hormuz “closed” again on Saturday — though US Central Command insists traffic is flowing normally, with 55 tankers and ~17m barrels transiting. Markets are shut for the weekend (US cash markets were also closed Friday for Juneteenth), so the last prints are Thursday’s — S&P 500 7,500.58, FTSE 100 10,363 — all framed by the week’s dominant macro fact: Kevin Warsh’s hawkish Fed debut, which held rates at 3.50–3.75% but tilted the dots toward a hike and has markets pricing roughly even odds of a September move.
Weekend edition. Equity indices are Thursday 18 June’s closes (US stock & bond markets were shut Friday 19 for Juneteenth and reopen Monday 22); European indices, gilts, crude, gold and FX reflect Friday’s session and the live overnight read. The swing factors into Monday: whether today’s Switzerland talks produce a durable framework or Lebanon/Hormuz deteriorate further, the durability of post-Warsh rate-hike pricing, and oil’s response to the headlines.
Top of the morning
US–Iran talks open in Switzerland today — with Lebanon first on the agenda
After a week of brinkmanship, technical negotiations begin Sunday: Iran’s delegation, led by parliament speaker Mohammad Bagher Ghalibaf, has left Tehran, and JD Vance is due at the venue. Diplomats say an emergency session on the Israel–Hezbollah fighting has been moved to the opening of day one — Tehran insists it will not go further while Israel keeps bombarding southern Lebanon. The talks build on a 14-point memorandum signed earlier in the week; no formal end to the war is signed yet, and the 60-day clock keeps running.
Iran says Hormuz is “closed” — the US says it’s flowing
Iran’s military declared the Strait of Hormuz shut again on Saturday in response to Israel’s Lebanon strikes, but US Central Command flatly contradicted it, saying 55 commercial vessels carrying more than 17m barrels transited normally. That gap — rhetorical closure versus physical flow — is what keeps the oil bid contained: Brent steadied near $80 and WTI near $77 late last week. The disinflation dividend is still visible at the margin, with FT noting fertiliser and urea prices back to prewar levels, even if the demand drop behind it “is not good news.”
Warsh’s hawkish Fed resets the rates regime
The first FOMC under Kevin Warsh held at 3.50–3.75% but stripped the easing bias: nine of nineteen policymakers now pencil in at least one hike by year-end, and CME pricing flipped to roughly even odds (~49%) of a September move, up from ~27% the day before. The trigger is inflation near 4.2% — a three-year high — pushed up by the spring energy shock. Warsh scrapped explicit forward guidance, withheld his own dot, and launched task forces to overhaul the Fed. The dollar is bid, gold whippy, and Treasuries cheaper.
Travel demand shrugs off the Iran crisis — a quiet positive for your book
FT reports holiday bookings are surging across the eastern Mediterranean even in markets close to the conflict, as travellers reassess the threat and proximity. It’s a small but real read-through to resilient discretionary demand — relevant to the online-travel complex (Booking) — and a counterpoint to the risk-off framing the Middle East headlines imply.
Washington escalates the transatlantic pharma-pricing fight
A US Section 301 investigation into Germany’s spending on new medicines — alleging chronic underpayment for innovative drugs — layers a fresh policy overhang onto European branded-drug economics, just as the sector already navigates US most-favoured-nation pressure. A theme to watch for any pharma holding; Chancellor Merz is pushing back, citing the EU trade pact.
Europe vs the US card networks; the chip “performance tussle” returns
Bloomberg’s Big Take has Europe hunting alternatives to Visa and Mastercard on payment-sovereignty grounds — no near-term catalyst, but a structural watch-item for the duopoly. Separately, chipmakers are reopening a public benchmarking fight that Nvidia’s dominance had quashed, a sign competition in AI hardware is heating up again.
AI’s next bottleneck is people — and the funding wave keeps building
FT argues workers are emerging as the next big AI logjam: Big Tech suddenly needs trades and crafts skills to build and maintain data centres fast enough. The capital side keeps stretching too — SpaceX is plotting a ≥$20bn bond after its record IPO, OpenAI and Anthropic float-chatter is live, and MSCI just handed SpaceX its lowest possible ESG score. A capex-and-credit wave with execution and policy strings attached.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. Higher-for-longer is firmly back — and, unusually, the tail is now a hike, not a cut. Warsh’s hawkish hold (easing bias gone, dots tilted up, ~49% odds of a September move, inflation 4.2%) keeps the dollar bid and argues for continued duration caution. FT’s Katie Martin (“Markets get the measure of Trump”) frames the two-way risk: investors now pounce the instant the president looks to be buckling on a foreign-policy stance — exactly the reflex being tested as the Iran process lurches between ceasefire and Hormuz closure. The energy offset is real but capped: crude is bid on the Lebanon flare-up, yet US insistence that Hormuz is flowing keeps the war premium contained, and fertiliser prices are back to prewar levels. The credit/regime flag for your war-chest discipline stays amber, not red: froth in AI-linked and private credit is visible (SpaceX’s ≥$20bn bond, PE dividend recaps), but no severe systemic trigger fired this weekend. Net: stance stays neutral-to-defensive, war-chest rules sheathed.
Travel / consumer (Booking — single name live). FT’s “holiday bookings surge in markets hit by Iran crisis” is a genuine demand signal: an eastern-Mediterranean rebound as travellers reprice the conflict. Read-through is constructive for online travel — resilient discretionary spend even in the shadow of the Gulf crisis.
Healthcare / pharma (Novo Nordisk, Eli Lilly, UnitedHealth, Vertex, Thermo Fisher — theme + names). Three threads. The US Section 301 probe of Germany’s drug pricing escalates the transatlantic war and overhangs European branded-drug economics. UnitedHealth’s $3bn AI push (bots calling doctors) is an efficiency play carrying execution and PR risk. And pharma M&A heat persists — FT reports cancer biotech Revolution Medicines rebuffing sale talk after Merck’s unsuccessful ~$32bn approach. The GLP-1 single-name action is a clinical readout — see the desk below.
AI capex & cloud (Microsoft, Alphabet, Amazon, Broadcom — theme). Demand is intact; the watch-items are the labour and funding bottlenecks. FT flags a coming data-centre workforce crunch, while the float/credit wave (SpaceX bond, OpenAI/Anthropic) leans the capex cycle ever harder on credit a higher-for-longer Fed makes more fragile.
Semiconductors (ASML, Broadcom — theme). Bloomberg notes chipmakers reopening a performance-benchmarking fight as Nvidia’s grip loosens — a sign of intensifying competition through the AI-hardware chain. No held-name catalyst today, but the read is more contest, not less.
Payments (Visa, Mastercard) · slow-burn risk. Europe is again pressing to loosen America’s grip on payment rails on sovereignty grounds. Structural, not imminent — but a standing watch-item for the duopoly.
Shelf single-names live today: Booking (eastern-Med travel rebound) and UnitedHealth ($3bn AI deployment). Everything else is theme-level — a GLP-1/obesity readout in the clinical desk, a US–Germany pharma-pricing probe, an AI capex/labour/IPO-supply watch, a semis competition signal, and the payments-sovereignty slow burn.
Net: the relief trade is on trial again — talks live in Switzerland, Hormuz contested, Lebanon flaring — but it’s a wobble, not a regime change, and no severe trigger fired. A hawkish Warsh Fed, a firm dollar and a hike-skewed curve keep the regime neutral-to-defensive; war-chest rules stay sheathed. Watch-lines: today’s talks outcome (or further Lebanon escalation), post-Warsh rate-hike pricing and the 10-year, oil’s Hormuz response, the US–Germany pharma probe, and AI IPO/bond supply.
Markets snapshot
Context read this morning from the live Bloomberg Europe page; levels cross-checked via web search. Equity indices are Thursday 18 June closes (US shut Friday for Juneteenth); European indices, gilts, FX, crude and gold reflect Friday’s session and the overnight read.
Instrument
Last
Move / context
S&P 500
7,500.58
+1.1% · Thu close; chip-led bounce (US shut Fri)
Nasdaq Composite
≈26,518
+1.9% · Thu close
FTSE 100
10,363.27
−0.35% Fri · Europe heavier into the weekend
US 10-year Treasury
4.46%
Warsh hawkish regime · Sep-hike odds ~49%
Fed funds target
3.50–3.75%
held; dots tilt toward a hike by year-end
EUR/USD
≈1.14
dollar near multi-month high on hawkish Fed
Brent crude
~$80
bid on Lebanon; capped as US says Hormuz flows · WTI ~$77
Gold (spot)
~$4,300
rebounded from a multi-month low near $4,100 post-Fed
Levels read this morning from the Bloomberg Europe page and cross-checked via web search; FX is an overnight approximation. The week’s signature is a split screen: a hawkish Warsh Fed keeping the dollar bid and the curve hike-skewed, set against a Gulf process that swung from ceasefire to a contested Hormuz closure over the weekend. With the US shut Friday for Juneteenth, the next live Wall Street session is Monday 22 — the first read on both the post-Warsh rate path and today’s talks.
Global markets & macro
The rates regime Kevin Warsh reset on Wednesday is still doing the heavy lifting. The Fed held but stripped out its easing bias, dropped explicit forward guidance, and published projections in which at least one further hike is now a live scenario for nearly half the committee — a response to inflation running near 4.2%, roughly double target, after the spring energy shock. Markets have internalised it: futures now price about even odds of a September hike (up from a quarter the day before), the dollar is bid, Treasuries are cheaper at a ~4.46% ten-year, and gold — which sank to a multi-month low near $4,100 on the decision — has clawed back toward $4,300. US equities, last printing Thursday before the Juneteenth close, still managed a chip-led bounce (S&P +1.1%, Nasdaq +1.9%); Europe was heavier on Friday, with the FTSE 100 off 0.35%. The standout domestic stress remains the UK, where record monthly borrowing and the Burnham-driven challenge to Keir Starmer are layering a fiscal-risk premium into gilts that bond markets are watching closely.
The energy side is where the weekend’s drama concentrated. Crude, which spent much of last week pricing a coming glut as Hormuz traffic resumed, found a bid again once southern Lebanon flared and Iran declared the strait shut — but the move is capped by US Central Command’s insistence that tankers are transiting normally. That tension — rhetorical closure against physical flow — is the key swing factor into Monday’s reopen. Underneath the indices, the capital-markets plumbing keeps rewriting itself on credit: SpaceX is preparing a bond of at least $20bn after its record IPO, OpenAI and Anthropic float-chatter is live, and FT now flags a looming data-centre labour crunch on top of the capital one. The confidence vote on compute is real, but it concentrates risk in exactly the corner — private and AI-linked credit — that a higher-for-longer Fed makes more fragile.
Geopolitics & world news
The transactional peace in the Gulf reaches a hinge point today. US and Iranian negotiators convene in Switzerland, with Vance attending and an emergency session on the Israel–Hezbollah fighting moved to the opening of day one — a sign of how central Lebanon has become to whether the broader deal holds. Tehran, which made a Lebanon truce a condition of the interim accord, says it will not go further while Israel keeps striking; the negotiations build on a 14-point memorandum signed last week, but no formal end to the war is sealed, and the 60-day clock keeps ticking. The contested Hormuz closure — declared by Iran, denied by US Central Command — is the market’s live barometer of whether the process is fraying or merely posturing.
Around it, the political map keeps shifting. Giorgia Meloni escalated a personal spat with Trump, telling him to focus on his own problems after he claimed she “begged” for a photo — a rare open G7 breach. In Spain, a court ordered Prime Minister Pedro Sánchez’s wife to face a corruption trial and surrender her passport, deepening his domestic crisis. In Britain, pressure on Starmer to set an exit timetable is building after Andy Burnham’s by-election win. And the war in Ukraine grinds on in a new key: Kyiv struck a refinery some 2,000km inside Russia, while FT charts how Putin’s manpower advantage is being eroded by Ukrainian drone innovation. For the medical reader, the public-health watch is sourced rather than speculative this morning: NEJM’s current issue carries field reports on Sudan virus disease in Uganda and an Andes hantavirus outbreaks update — a reminder the surveillance dial is always turning. The clinical deep-dive follows.
Clinical desk · NEJM this week
For the medical reader
Read this morning from both pinned NEJM feeds via Control Chrome — the current-issue eTOC (Vol 394, No 24, 18 June 2026) and the cardiology/ahead-of-print feed, which this week is unusually rich in structural and interventional cardiology, metabolic medicine and a first-in-human gene-editing readout. The feeds carry titles and short standfirsts; each headline result below was looked up against the NEJM abstract and conference/registry coverage (ACC 2026, ESC, Healio, TCTMD). Numbers are summarised, not reproduced.
SYNCHRONIZE-1 — survodutide in obesity (positive; metabolic, GLP-1 complex). A phase 3, placebo-controlled trial of the once-weekly glucagon/GLP-1 dual agonist in adults with obesity without diabetes. At 76 weeks the top 6.0 mg dose cut body weight by ~16.6% vs 3.2% on placebo (P<0.001), with 28.5% of patients losing ≥20% of weight (vs 6.6%); visceral fat fell up to 34% and liver fat up to ~63%, with only modest lean-mass loss. Takeaway: a credible third entrant in the obesity race (Boehringer Ingelheim/Zealand), though the headline ~16.6% trails tirzepatide’s >20% — a competitive read for the whole GLP-1 shelf rather than a leader-unseating one.
CHAMPION-AF — left atrial appendage closure vs anticoagulation (positive; practice-relevant). 3,000 patients with AF eligible for long-term anticoagulation, randomised to a Watchman FLX device or a NOAC across 16 countries. LAAC was noninferior for the composite of cardiovascular death, stroke or systemic embolism and superior for non–procedure-related bleeding; the net clinical-benefit composite favoured the device (15.1% vs 21.8%), driven by less clinically-relevant nonmajor bleeding (7.0% vs 14.2%), with 98.8% procedural success and no procedure-related deaths. Takeaway: the strongest signal yet that closure is a frontline alternative to lifelong blood-thinners in suitable patients — not just the anticoagulation-intolerant.
ODYSSEY-HCM — mavacamten in nonobstructive HCM (negative; important). A phase 3, placebo-controlled trial across 201 sites in symptomatic nonobstructive hypertrophic cardiomyopathy. The cardiac myosin inhibitor missed both co-primary endpoints at 48 weeks — no significant gain in peak oxygen consumption or in patient-reported health status (KCCQ) — despite clear biology (lower myocardial-stress biomarkers, modest reverse remodelling). Takeaway: “biology improved, patients did not.” Mavacamten (BMS) stays confined to the obstructive phenotype, and nonobstructive HCM remains without a disease-modifying drug.
VERVE-102 (Heart-2) — in vivo base editing of PCSK9 (landmark; first-in-human-scale). A phase 1b study in 35 patients with heterozygous familial hypercholesterolaemia or premature coronary disease, given a single infusion of a liver-targeted base editor that permanently switches off PCSK9. Dose-dependent mean PCSK9 reductions ran 51–88%, with LDL-C down up to 62% (an absolute fall of ~78 mg/dL) at the top dose and effects durable to 18 months; no dose-limiting toxicity, with mild infusion reactions and transient ALT rises. Takeaway: proof-of-concept for “one-and-done” genetic LDL lowering (Lilly, via Verve) — potentially paradigm-shifting if larger trials hold.
FIND-CKD — finerenone in non-diabetic CKD (positive; cardiorenal). In adults with chronic kidney disease but without diabetes, the nonsteroidal mineralocorticoid-receptor antagonist produced a significantly slower decline in eGFR than placebo over 32 months, with a safety profile in line with prior trials. Takeaway: extends finerenone (Bayer) beyond the diabetic kidney-disease label where it was first established — a meaningful population-broadening signal for a cardiorenal mainstay.
OPTIMAL & IVUS-CHIP — imaging-guided PCI (neutral; cath-lab relevant). Two randomised trials testing whether intravascular ultrasound beats angiography to guide stenting. In unprotected left-main disease (OPTIMAL) and in complex high-risk PCI (IVUS-CHIP), IVUS guidance did not lower ischaemic events or target-vessel failure versus angiography. Takeaway: a consistent pair of null results that tempers enthusiasm for routine IVUS in these specific settings, even as imaging retains a role in selected anatomy.
Also in the issue and ahead-of-print queue: TRACTION (a hospital policy of pre-op tranexamic acid cut transfusion in major noncardiac surgery, noninferior for VTE); the LOGICAL trial (conservative vs liberal oxygen after cardiac arrest — neutral on 180-day survival); pulsed-field ablation as initial therapy for persistent AF; a randomised trial of endovascular stenting for post-thrombotic syndrome with a “step forward” editorial; SCOUT-HCM (mavacamten in adolescents with obstructive HCM); plus reviews on anticoagulation-reversal antidotes and differentiated thyroid cancer, and a perspective on race-based drug dosing.
Provenance: read this morning from Luca’s two pinned NEJM feeds (current-issue eTOC and cardiology/ahead-of-print) via Control Chrome; every result cross-checked via web search against NEJM abstracts and ACC 2026 / ESC / Healio / TCTMD coverage. Summarised, not reproduced verbatim; not clinical advice.
Today & week ahead (CET)
Sun 21US–Iran talks open in Switzerland (Vance attending; Lebanon emergency session first) · markets closed · Colombia presidential runoff
Mon 22US stock & bond markets reopen — first live read on post-Juneteenth positioning, the post-Warsh rate path and the talks · quiet data slate
Tue 23Flash PMIs — Germany, Eurozone, UK and US (June)
Wed 24Australia CPI · ECB speakers
Thu 25US PCE price index (May) — the key inflation print under the hawkish Fed · final US Q1 GDP · Japan CPI
WatchSwitzerland talks outcome & Lebanon/Hormuz · post-Warsh rate-hike pricing & the 10-year · oil’s Hormuz response · UK gilts & Starmer’s position · US Section 301 pharma probe of Germany · AI IPO/bond supply (SpaceX, OpenAI, Anthropic)